Consent given pursuant to Sections 14 and 14A for the importation and supply of the therapeutic goods specified by Boucher & Muir

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth of Australia Parliament, was introduced to regulate the import, supply, and sale of therapeutic goods in Australia, ensuring their quality, safety, and efficacy. The Act addresses issues related to the provision of therapeutic goods by establishing a regulatory framework that controls their development, production, and distribution. In this context, Section 14 and 14A of the Act provides a mechanism for granting consent for importing and supplying therapeutic goods that do not fully comply with specified regulations, under certain conditions to mitigate any potential risks. The delegate of the Secretary of the Department of Health exercised this authority on 10 March 2015, granting Boucher & Muir Pty Ltd consent to import and supply a batch of ursodeoxycholic acid capsules that did not meet the labelling requirements of the Therapeutic Goods Order No. 69. This consent was subject to conditions to ensure that appropriate information was disseminated to healthcare professionals. The policy objective underlying the Therapeutic Goods Act 1989 is to safeguard public health by providing a regulatory system that ensures therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy. This objective is evident in the Act's provisions that allow for exceptions to regulatory requirements under controlled circumstances, as demonstrated in the case of Boucher & Muir Pty Ltd's consent to supply a batch of non-compliant ursodeoxycholic acid capsules. By imposing conditions on such consents, the Act seeks to balance the need for regulatory compliance with the practicalities of therapeutic goods supply, ultimately protecting public health while facilitating access to necessary medical treatments.

Scope and Application

The Therapeutic Goods Act 1989, as modified by the gazetted notice on 10 March 2015, applies to the import and supply of therapeutic goods within the Commonwealth of Australia. In this instance, the Act facilitates a specific consent for Boucher & Muir Pty Ltd to import and supply a specified batch of ursodeoxycholic acid (URSOSAN) 250 mg capsule blister packs that do not conform to certain labelling requirements under Therapeutic Goods Order No. 69. This consent is narrowly tailored to address a non-compliance issue with the blister foil label of a particular batch, specifically the omission of the batch number prefix. The consent is limited in scope and duration, being effective from 10 March 2015 until the supply of the specified batch is exhausted. The Act's application is further refined by conditions imposed by the delegate of the Secretary, who mandates the distribution of a 'Dear Healthcare Professional' letter to ensure appropriate communication regarding the non-compliance and its implications. This demonstrates the Act's role in balancing regulatory compliance with the practicalities of therapeutic goods distribution within Australia.

Key Provisions

The Therapeutic Goods Act 1989, in its Sections 14 and 14A, provides a mechanism for consent to be given by the delegate of the Secretary of the Department of Health, in this instance concerning the importation and supply of ursodeoxycholic acid (URSOSAN) 250 mg capsule blister packs. The consent granted to Boucher & Muir Pty Ltd allows for the supply of a specified batch of the product which does not conform to the labelling requirements under paragraph 3(13) of the Therapeutic Goods Order No. 69—General requirements for labels for medicines (subsection 14(1)). This consent is conditional and effective from 10 March 2015 until the supply of the batch is exhausted (subsection 14A(1)). Under the conditions of the consent, Boucher & Muir Pty Ltd must distribute a "Dear Healthcare Professional" letter, identical to the one provided to the Therapeutic Goods Administration (TGA) on 9 March 2015. This letter, which includes specific labelling information, must be disseminated as directed in an email sent on the same day (subsection 15(1)). The labels referred to in the letter of 14 February 2015 must be used for the product covered by this consent. The obligations imposed by the Therapeutic Goods Act 1989 on Boucher & Muir Pty Ltd include the adherence to the specific conditions outlined in the consent. These conditions mandate the distribution of the "Dear Healthcare Professional" letter to ensure that healthcare professionals are informed about the non-conformity of the product batch and the corrective measures in place. Additionally, the company must ensure that the product supplied adheres to the labels specified in the letter of 14 February 2015, thereby mitigating any potential risks associated with the non-compliance of the batch number prefix on the blister foil label. Failure to comply with the conditions set out in the consent may result in significant legal repercussions. Under the Therapeutic Goods Act 1989, non-compliance can lead to civil or criminal penalties. The specific consequences of breaching the Act are not detailed in the provided text, but generally, the penalties for non-compliance with therapeutic goods regulations can include fines and imprisonment, depending on the severity and intent of the breach. The maximum penalties are outlined in the relevant sections of the Act and related regulations, and these can vary widely based on the nature of the offence.